vTv Therapeutics Inc. (NASDAQ:VTVT) will be releasing its earnings data on Tuesday, October 31st. Analysts expect vTv Therapeutics to post earnings of ($0.42) per share for the quarter.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.19 million. On average, analysts expect vTv Therapeutics to post $-1.21 EPS for the current fiscal year and $-1.53 EPS for the next fiscal year.
Shares of vTv Therapeutics Inc. (VTVT) opened at 6.61 on Monday. vTv Therapeutics Inc. has a 12-month low of $3.57 and a 12-month high of $8.09. The firm’s 50-day moving average is $6.40 and its 200-day moving average is $6.40. The firm’s market cap is $64.07 million.
VTVT has been the subject of several research analyst reports. Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “sell” rating in a research note on Wednesday, July 5th. HC Wainwright set a $13.00 target price on vTv Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $15.00 target price on shares of vTv Therapeutics in a research note on Friday, August 4th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $14.50.
In other news, major shareholder Ronald O. Perelman acquired 85,000 shares of vTv Therapeutics stock in a transaction that occurred on Friday, August 11th. The shares were purchased at an average cost of $4.13 per share, for a total transaction of $351,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of vTv Therapeutics stock in a transaction that occurred on Tuesday, August 15th. The shares were purchased at an average price of $4.72 per share, for a total transaction of $236,000.00. The disclosure for this purchase can be found here. Insiders have purchased 165,000 shares of company stock worth $728,150 over the last 90 days. 0.80% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in vTv Therapeutics stock. State Street Corp boosted its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,016 shares of the biotechnology company’s stock after buying an additional 1,976 shares during the period. State Street Corp owned 1.01% of vTv Therapeutics worth $486,000 as of its most recent SEC filing. 11.05% of the stock is currently owned by institutional investors and hedge funds.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
What are top analysts saying about vTv Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for vTv Therapeutics Inc. and related companies.